Battery manufacturer Accutronics is targeting the traditional markets occupied by lead-acid with its replacement lithium iron phosphate (LiFePo4) technology.
The UK company’s Ultralife battery is designed for the security, medical and defence applications that currently use sealed lead-acid batteries.
The range of six batteries— 12.8V from 96Wh to 1280Wh, and a 6.4V model at 29Wh— are being manufactured by its parent company US battery firm Ultralife.
Ultralife Corporation bought all of the outstanding shares of Accutronics Ltd., for £7.575 million ($11 million) in cash this January.
Neil Oliver, technical marketing manager of Accutronics, said: “Many critical or remote devices that use SLA batteries face problems with longevity.
“While they may seem like a quick and easy solution for powering devices, they typically require maintenance and servicing every two years. When you consider the associated expense of this, it makes for a relatively high total cost of ownership.
“LIFePO4 batteries remain effective up to three times longer with less cell degradation over time, while still delivering a similar charging voltage to SLA solutions. This removes any redesign costs for devices upgrading to LIFePO4.”